Key Takeaways
- Corvus Pharmaceuticals Inc (CRVS) reported 75% EASI-75 response in Phase 1 atopic dermatitis and raised $201 million in January 2026, extending its cash runway into 2027+.
- CRVS stock surged more than 200% in early 2026 as investors repriced its oral ITK inhibitor opportunity.
- Erasca Inc (ERAS) secured $258.8 million in fresh capital and holds patent protection on ERAS-4001 through 2043.
- ERAS stock is now backed by a projected cash runway into the second half of 2028, with key Phase 1 oncology data expected in 2026.
Introduction
The 2026 biotech rebound is not being driven by speculation. It is being driven by clinical data, stronger balance sheets, and improving capital market conditions.
After a difficult 2022–2024 funding cycle marked by rising interest rates, small-cap biotech stocks are regaining investor attention. Stabilizing macro conditions and clearer FDA oncology pathways have allowed companies with credible pipelines to raise substantial capital.
Two clinical-stage biotech stocks exemplify this shift: Corvus Pharmaceuticals (CRVS) in immunology and T-cell oncology, and Erasca (ERAS) in precision RAS-driven cancers.
Both companies remain unprofitable. Both are entirely dependent on clinical success. But both now have the financial resources and early validation that investors look for in high-risk, high-reward biotech investments.
Understanding Clinical-Stage Biotech Stocks
Clinical-stage biotech companies generate little or no recurring revenue. Their value is tied to pipeline’s probability of success.
Expenses are dominated by R&D and clinical trial costs. Quarterly net losses of $10–$40 million are common at this stage. Financing typically comes from public equity offerings, which dilute shareholders but extend operational runway.
Valuation is rarely based on current earnings. Instead, investors model:
- Peak sales potential
- Probability-adjusted approval odds
- Time to commercialization
- Competitive landscape
This framework explains why strong Phase 1 or Phase 2 data can reprice a stock by 100% or more in weeks.
Sector Drivers in 2026
Three forces are supporting clinical-stage biotech stocks in 2026.
First, interest rate stabilization has reopened equity markets. Companies are now able to raise $200–$300 million offerings without extreme discounts.
Second, the FDA has signaled support for streamlining oncology approvals, particularly in areas of high unmet need.
Third, large pharmaceutical companies are actively seeking pipeline assets, especially in immunology and RAS oncology, where competition is intense but opportunities remain substantial.
Against this backdrop, Corvus Pharmaceuticals and Erasca executed significant capital raises in January 2026, positioning themselves for multi-year development.
Corvus Pharmaceuticals (CRVS)
Corvus Pharmaceuticals Inc (CRVS) is developing soquelitinib, an oral inhibitor of Interleukin-2-inducible T-cell kinase (ITK).
ITK plays a central role in T-cell signaling. By selectively inhibiting this pathway, Corvus aims to treat immune-mediated diseases such as atopic dermatitis and T-cell lymphomas without the need for injectable biologics.
The company does not have FDA-approved products. Its entire valuation rests on the success of soquelitinib across oncology and immunology indications.
Financial Performance and Capital Position
In Q3 2025, Corvus reported a net loss of $10.2 million, or -$0.12 per share, compared with a $40.2 million loss one year earlier. This marked a substantial operational improvement and beat analyst expectations of -$0.14 per share.
As of late 2025, cash stood at $65.7 million. In January 2026, Corvus completed a $201 million upsized public offering. Pro forma cash levels now likely support operations into 2027 or beyond, reducing near-term dilution risk.
Clinical Data and Pipeline Progress
The major inflection point came on January 20, 2026, when Phase 1 data in atopic dermatitis showed that 75% of patients achieved EASI-75 after eight weeks.
For context, many injectable biologics achieve comparable response rates but require ongoing injections. An effective oral alternative could compete in a multibillion-dollar global market.
Corvus is now initiating a Phase 2 trial in atopic dermatitis while continuing a registration-enabling Phase 3 trial in Peripheral T-cell Lymphoma. Interim Phase 3 data are expected in late 2026, representing the company’s fastest potential route to approval.
Valuation and Market Perspective
CRVS stock rose more than 200% in early 2026, trading in the $17–$21 range after previously languishing in single digits.
Valuation frameworks differ. Discounted cash flow models suggest upside if soquelitinib reaches commercialization, with some intrinsic value estimates near $55 per share under optimistic scenarios. However, on a price-to-book basis above 20x, the stock reflects significant future expectations.
Consensus analyst ratings remain Buy or Strong Buy, with price targets ranging from $30 to $42 and an average around $35.70.
Corvus Pharmaceuticals is a high-volatility immunology and oncology play. Its risk profile centers on late-2026 clinical data.
Erasca (ERAS)
Erasca Inc (ERAS) is focused exclusively on cancers driven by the RAS/MAPK pathway, which accounts for approximately 30% of human malignancies.
Its pipeline includes ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor. Rather than targeting a single mutation, Erasca aims to inhibit multiple RAS mutations simultaneously to overcome resistance.
The company has deprioritized non-core programs to focus capital on its RAS franchise.
Financial Performance and Capital Position
For Q3 2025, Erasca reported a net loss of $30.6 million. Losses narrowed as R&D spending became more focused.
In January 2026, ERAS completed a $258.8 million upsized public offering. This extends its projected cash runway into the second half of 2028.
Patent protection for ERAS-4001 now extends through 2043 in the United States, strengthening long-term intellectual property positioning.
Clinical Momentum and Competitive Landscape
Early 2026 updates showed confirmed partial responses at low doses for ERAS-0015, indicating early biological activity and tolerability.
With a market capitalization exceeding $4 billion, ERAS is competing in a crowded RAS oncology space alongside companies like Revolution Medicines Inc (RVMD).
Upcoming monotherapy data in the first half of 2026 represent a key catalyst. Additional data from the BOREALIS-1 trial of ERAS-4001 are expected in the second half of 2026.
Valuation and Investment View
ERAS stock has reached 52-week highs during the February rally. Analyst ratings are generally Buy or Moderate Buy.
Price targets have recently been revised upward, with some estimates around $16.00 and an average near $10.51 before recent price appreciation.
Erasca represents a concentrated precision oncology investment. Its multi-year cash cushion provides stability, but ultimate valuation depends on sustained clinical efficacy.
Investment Strategy for High-Risk Biotech Stocks
Investing in clinical-stage biotech stocks requires strict risk management.
Position sizing should reflect binary trial outcomes. Even strong early data do not guarantee Phase 3 success.
Diversification across immunology and oncology reduces single-asset exposure. Monitoring cash runway is essential; companies funded for two to three years face less immediate dilution pressure.
Above all, investors should anchor decisions to clinical milestones rather than short-term price momentum.
Conclusion
The biotech rebound of 2026 reflects a return to fundamentals: capital discipline, validated science, and measurable patient outcomes.
Corvus Pharmaceuticals (CRVS) is attempting to replace injectable biologics with a targeted oral immunology therapy supported by 75% Phase 1 efficacy data. Erasca (ERAS) is pursuing one of oncology’s most ambitious goals—systematically dismantling the RAS pathway.
Both remain unprofitable. Both depend entirely on clinical success. But with $201 million and $258.8 million in fresh capital, respectively, they have secured the time needed to prove their science.
For investors focused on clinical-stage biotech stocks, these two companies illustrate how precision medicine and disciplined financing are defining the 2026 investment landscape.